eMedicine Specialties > Emergency Medicine > Ophthalmology

Retinal Artery Occlusion

Author: Neil Jain, MD, Staff Physician, Yale University School of Medicine, Department of Surgery, Section of Emergency Medicine
Coauthor(s): Pascal SC Juang, MD, FAAEM, FACEP, Medical Director, ED Information Systems, Attending Physician, Department of Emergency Medicine, Hoag Memorial Hospital Presbyterian
Contributor Information and Disclosures

Updated: Jun 30, 2009

Introduction

Background

Painless loss of monocular vision is the usual presenting symptom of retinal artery occlusion (RAO). Ocular stroke commonly is caused by embolism of the retinal artery, although emboli may travel to distal branches of the retinal artery, causing loss of only a section of the visual field. Retinal artery occlusion represents an ophthalmologic emergency, and delay in treatment may result in permanent loss of vision.

Immediate intervention improves chances of visual recovery, but, even then, prognosis is poor, with only 21-35% of eyes retaining useful vision. Although restoration of vision is of immediate concern, retinal artery occlusion is a harbinger for other systemic diseases that must be evaluated immediately.

Pathophysiology

Blood supply to the retina originates from the ophthalmic artery, the first intracranial branch of the internal carotid artery that supplies the eye via the central retinal and the ciliary arteries. The central retinal artery supplies the retina as it branches into smaller segments upon leaving the optic disc. The ciliary arteries supply the choroid and the anterior portion of the globe via the rectus muscles (each rectus muscle has 2 ciliary arteries except the lateral rectus, which has 1).

Anatomical variants include cilioretinal branches from the short posterior ciliary artery, giving additional supply to part of the macular retina. A cilioretinal artery occurs in approximately 14% of the population.

Typical funduscopic findings of a pale retina with a cherry red macula (ie, the cherry red spot) result from obstruction of blood flow to the retina from the retinal artery, causing pallor, and continued supply of blood to the choroid from the ciliary artery, resulting in a bright red coloration at the thinnest part of the retina (ie, macula). These findings do not develop until an hour or more after embolism, and they resolve within days of the acute event. By this time, visual loss is permanent and primary optic atrophy has developed. In those with a cilioretinal artery supplying the macula, a cherry red spot is not observed.


The cherry red spot of central retinal artery occ...

The cherry red spot of central retinal artery occlusion.

The cherry red spot of central retinal artery occ...

The cherry red spot of central retinal artery occlusion.


An embolism, atherosclerotic changes, inflammatory endarteritis, angiospasm, or hydrostatic arterial occlusion may occlude the retinal artery. The mechanism of obstruction may be obvious from comorbid systemic disease or physical findings. Atrial fibrillation and ipsilateral carotid stenosis are more commonly associated with prolonged visual disturbances.

Animal studies have shown that a retina with completely occluded circulation has irreversible ischemic damage at 105 minutes but may recover at 97 minutes. Complete occlusion of retinal artery circulation in humans is rare with retinal artery disease; thus, retinal recovery is possible even after days of ischemia.

Branch retinal artery occlusion (BRAO) occurs when the embolus lodges in a more distal branch of the retinal artery. BRAO typically involves the temporal retinal vessels and usually does not require ocular therapeutics unless perifoveolar vessels are threatened. The central retinal artery is affected in 57% of occlusions, the branch retinal artery is involved in 38% of occlusions, and cilioretinal artery obstructions occur in 5% of occlusions.

Frequency

United States

Recent estimates put the incidence of retinal artery occlusion at 0.85 per 100,000 per year, with a 10-year cumulative incidence of 1.5%.

Mortality/Morbidity

  • Patients with visualized retinal artery emboli, whether or not obstruction is present, have 56% mortality over 9 years, compared to 27% for an age-matched population without retinal artery emboli. Life expectancy of patients with central RAO (CRAO) is 5.5 years, compared to 15.4 years for an age-matched population without CRAO.
  • RAO is associated with smoking and cardiovascular disease, with an increased incidence of stroke in patients who have suffered RAO.
  • Both eyes have an equal incidence of disease, with bilateral involvement in 1-2%.

Sex

Men are affected slightly more frequently than women.

Age

  • The mean age of presentation of retinal artery occlusion is early in the seventh decade of life, although a few cases have been reported in patients younger than 30 years.
  • The etiology of occlusion changes, depending on the age at presentation.

Clinical

History

  • The most common presenting complaint is an acute persistent painless loss of vision. In central artery occlusions, visual loss is central and dense. In branch artery occlusions, visual loss may go unnoticed if only a section of the peripheral visual field space is affected.
  • A complete visual field defect suggests central retinal artery occlusion (CRAO).
  • A sectional visual field defect suggests branch retinal artery occlusion (BRAO) and may be an altitudinal defect affecting the upper or lower hemifield but never respecting a vertical axis.
  • A history of hypertension or diabetes mellitus is elicited in 67% and 25% of patients with CRAO, respectively.
  • Query about any medical problems that could predispose patients to embolus formation (eg, atrial fibrillation, endocarditis, coagulopathies, atherosclerotic disease).
  • Prolonged direct pressure to the globe during drug-induced stupor or improper positioning during surgery also may lead to CRAO.

Physical

  • Determine the degree of vision loss (eg, no light perception, hand movement, counting fingers); the prognosis for recovery is directly related to initial visual loss.
  • Document hand movement, finger counts, and visual fields at a standard distance of 1' to 3'. Documentation of distance will provide concise communication with consultants and for standardization of repeated examinations.
  • Funduscopic examination
    • An afferent pupillary defect (ie, paradoxical dilatation of the pupil when a light is shined from the unaffected eye to the affected eye) may be observed within seconds of the occlusive event.
    • The cherry red spot and a ground-glass retina are the classic findings but may take hours to develop.
    • The funduscopic findings typically resolve within days to weeks of the acute event, sometimes leaving a pale optic disc as the only physical finding.
    • Emboli can be observed in approximately 20% of patients with CRAO.
    • A dilated funduscopic examination is required to see the pathological signs of RAO.
    • BRAO presents with whitening of the retina along the distribution of the occluded vessel.
    • Boxcar segmentation of the blood column is observed most often in BRAO and is a sign of severe occlusion and slowing of circulation.
  • Direct the physical examination to evaluate for murmurs, carotid bruits, or other signs of cardiovascular disease.

Causes

Causes of central retinal artery occlusion (CRAO) vary, depending on the age of the patient. A detailed analysis of comorbid disease is necessary to elucidate the cause of the acute visual loss.

  • Embolism
    • Embolism is usually caused by cholesterol, but it can be calcific, bacterial, or talc from IV drug abuse.
    • It is associated with poorer visual acuity and higher morbidity and mortality than other retinal artery occlusions.
    • Embolus from the heart is the most common cause of CRAO in patients younger than 40 years.
    • Amaurosis fugax preceding persistent loss of vision suggests branch retinal artery occlusion (BRAO) or temporal arteritis and may represent emboli causing temporary occlusion of the retinal artery.
    • Coagulopathies from sickle cell anemia or antiphospholipid antibodies are common etiologies for CRAO in patients younger than 30 years.
  • Atherosclerotic changes
    • Carotid atherosclerosis is observed in 45% of CRAO cases, with 60% or more stenosis occurring in 20% of cases.
    • Atherosclerotic disease is the leading cause of CRAO in patients aged 40-60 years.
  • Inflammatory endarteritis
    • Occurrence is rare (only 2% of cases).
    • Suspect inflammatory endarteritis in elderly patients if no other etiology is observed.
    • Inflammatory endarteritis can affect the second eye within hours if untreated.
  • Migraines are rare causes of CRAO but are most common in patients younger than 30 years.
  • Hydrostatic arterial occlusion
  • Moya moya disease
  • Thrombophilia
  • Carotid dissection
  • Increased intraocular pressure (IOP) from glaucoma or prolonged direct pressure to the globe in unconscious patients can precipitate CRAO.
    • Low retinal blood pressure from carotid stenosis or severe hypotension may lead to CRAO.
    • Transection of the retinal artery, transection of the optic nerve, or retrobulbar hemorrhage can cause visual loss.

More on Retinal Artery Occlusion

Overview: Retinal Artery Occlusion
Differential Diagnoses & Workup: Retinal Artery Occlusion
Treatment & Medication: Retinal Artery Occlusion
Follow-up: Retinal Artery Occlusion
Multimedia: Retinal Artery Occlusion
References

References

  1. Biousse V, Calvetti O, Bruce BB, Newman NJ. Thrombolysis for central retinal artery occlusion. J Neuroophthalmol. Sep 2007;27(3):215-30. [Medline].

  2. Beiran I, Goldenberg I, Adir Y, Tamir A, Shupak A, Miller B. Early hyperbaric oxygen therapy for retinal artery occlusion. Eur J Ophthalmol. Oct-Dec 2001;11(4):345-50. [Medline].

  3. Hattenbach LO, Kuhli-Hattenbach C, Scharrer I, Baatz H. Intravenous thrombolysis with low-dose recombinant tissue plasminogen activator in central retinal artery occlusion. Am J Ophthalmol. Nov 2008;146(5):700-6. [Medline].

  4. Atebara NH, Brown GC, Cater J. Efficacy of anterior chamber paracentesis and Carbogen in treating acute nonarteritic central retinal artery occlusion. Ophthalmology. Dec 1995;102(12):2029-34; discussion 2034-5. [Medline].

  5. Augsburger JJ, Magargal LE. Visual prognosis following treatment of acute central retinal artery obstruction. Br J Ophthalmol. Dec 1980;64(12):913-7. [Medline].

  6. Beiran I, Reissman P, Scharf J, et al. Hyperbaric oxygenation combined with nifedipine treatment for recent-onset retinal artery occlusion. Eur J Ophthalmol. Apr-Jun 1993;3(2):89-94. [Medline].

  7. Brown GC. Retinal artery obstructive disease. In: Ryan SJ, ed. Retina. Vol 2. St. Louis: Mosby; 1994:1361-77.

  8. Brown GC, Magargal LE, Shields JA, et al. Retinal arterial obstruction in children and young adults. Ophthalmology. Jan 1981;88(1):18-25. [Medline].

  9. Butz B, Strotzer M, Manke C, et al. Selective intraarterial fibrinolysis of acute central retinal artery occlusion. Acta Radiol. Nov 2003;44(6):680-4. [Medline].

  10. Cella W, Avila M. Optical coherence tomography as a means of evaluating acute ischaemic retinopathy in branch retinal artery occlusion. Acta Ophthalmol Scand. Nov 2007;85(7):799-801. [Medline].

  11. Ffytche TJ, Bulpitt CJ, Kohner EM, et al. Effect of changes in intraocular pressure on the retinal microcirculation. Br J Ophthalmol. May 1974;58(5):514-22. [Medline].

  12. Fraser S, Siriwardena D. Interventions for acute non-arteritic central retinal artery occlusion. Cochrane Database Syst Rev. 2002;CD001989. [Medline].

  13. Hayreh SS, Kolder HE, Weingeist TA. Central retinal artery occlusion and retinal tolerance time. Ophthalmology. Jan 1980;87(1):75-8. [Medline].

  14. Hertzog LM, Meyer GW, Carson S, et al. Central retinal artery occlusion treated with hyperbaric oxygen. J Hyperbaric Med. 1992;7:33-42.

  15. Klein R, Klein BE, Moss SE, Meuer SM. Retinal emboli and cardiovascular disease: the Beaver Dam Eye Study. Arch Ophthalmol. Oct 2003;121(10):1446-51. [Medline].

  16. Knoop K, Trott A. Ophthalmologic procedures in the emergency department--Part I: Immediate sight-saving procedures. Acad Emerg Med. Jul-Aug 1994;1(4):408-12. [Medline].

  17. Lacy C, Armstrong LL, Ingram N, et al. Drug Information Handbook. 4th ed. Hudson, Cleveland: Lexi-Comp Inc; 1996.

  18. Magargal LE, Goldberg RE. Anterior chamber paracentesis in the management of acute nonarteritic central retinal artery occlusion. Surg Forum. 1977;28:518-21. [Medline].

  19. Mangat HS. Retinal artery occlusion. Surv Ophthalmol. Sep-Oct 1995;40(2):145-56. [Medline].

  20. Mead GE, Lewis SC, Wardlaw JM, Dennis MS. Comparison of risk factors in patients with transient and prolonged eye and brain ischemic syndromes. Stroke. Oct 2002;33(10):2383-90. [Medline].

  21. Miyake Y, Horiguchi M, Matsuura M, et al. Hyperbaric oxygen therapy in 72 eyes with retinal arterial occlusion. 9th International Symposium on Underwater and Hyperbaric Physiology. 1987;949-53.

  22. Rumelt S, Brown GC. Update on treatment of retinal arterial occlusions. Curr Opin Ophthalmol. Jun 2003;14(3):139-41. [Medline].

  23. Schmidt D, Schumacher M, Wakhloo AK. Microcatheter urokinase infusion in central retinal artery occlusion. Am J Ophthalmol. Apr 15 1992;113(4):429-34. [Medline].

  24. Schmidt DP, Schulte-Monting J, Schumacher M. Prognosis of central retinal artery occlusion: local intraarterial fibrinolysis versus conservative treatment. AJNR Am J Neuroradiol. Sep 2002;23(8):1301-7. [Medline].

  25. Suri MF, Nasar A, Hussein HM, Divani AA, Qureshi AI. Intra-arterial thrombolysis for central retinal artery occlusion in United States: Nationwide In-patient Survey 2001-2003. J Neuroimaging. Oct 2007;17(4):339-43. [Medline].

  26. Wray SH. The management of acute visual failure. J Neurol Neurosurg Psychiatry. Mar 1993;56(3):234-40. [Medline].

Further Reading

Keywords

retinal artery occlusion, RAO, branch retinal artery occlusion, BRAO, central retinal artery occlusion, CRAO, retinal disease, arterial occlusive disease, ocular stroke, embolism of the retinal artery, retinal artery emboli, loss of vision

Contributor Information and Disclosures

Author

Neil Jain, MD, Staff Physician, Yale University School of Medicine, Department of Surgery, Section of Emergency Medicine
Neil Jain, MD is a member of the following medical societies: American College of Emergency Physicians and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Coauthor(s)

Pascal SC Juang, MD, FAAEM, FACEP, Medical Director, ED Information Systems, Attending Physician, Department of Emergency Medicine, Hoag Memorial Hospital Presbyterian
Pascal SC Juang, MD, FAAEM, FACEP is a member of the following medical societies: American Academy of Emergency Medicine and American College of Emergency Physicians
Disclosure: Nothing to disclose.

Medical Editor

Assaad J Sayah, MD, Chief, Department of Emergency Medicine, Cambridge Health Alliance
Assaad J Sayah, MD is a member of the following medical societies: National Association of EMS Physicians
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Douglas Lavenburg, MD, Clinical Professor, Department of Emergency Medicine, Christiana Care Health Systems
Douglas Lavenburg, MD is a member of the following medical societies: American Society of Cataract and Refractive Surgery
Disclosure: Nothing to disclose.

CME Editor

John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center
John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Chief Editor

Robert E O'Connor, MD, MPH, Professor and Chair, Department of Emergency Medicine, University of Virginia Health System
Robert E O'Connor, MD, MPH is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American College of Physician Executives, American Heart Association, American Medical Association, Medical Society of Delaware, National Association of EMS Physicians, Society for Academic Emergency Medicine, and Wilderness Medical Society
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.